Relmada Therapeutics prices 29.47M shares at $4.75 in private placement

Relmada Therapeutics (RLMD) has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $160M to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from Venrock Healthcare Capital Partners, Commodore Capital, Janus Henderson Investors, RA Capital Management, Balyasny Asset Management, OrbiMed, Spruce Street Capital, Squadron Capital Management, Columbia Threadneedle Investments, Adage Capital Management, Marshall Wace, Braidwell LP, Great Point Partners and Eventide Asset Management. Pursuant to the terms of the securities purchase agreement, Relmada is selling an aggregate of 29,474,569 shares of its common stock at a purchase price of $4.75 per share and pre-funded warrants to purchase 4,210,527 shares of Common Stock at a purchase price of $4.749 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share. The PIPE financing is expected to close on or about March 11, 2026, subject to satisfaction of customary closing conditions. Jefferies, Leerink Partners, Piper Sandler and Mizuho are acting as placement agents for the PIPE financing.